- |||||||||| Empliciti (elotuzumab) / AbbVie, BMS
Trial termination: A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies. (clinicaltrials.gov) - Aug 21, 2012 P1/2, N=28, Terminated, Active, not recruiting --> Completed Active, not recruiting --> Terminated; Enrollment has been halted
- |||||||||| Enrollment closed: Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Aug 16, 2012
P1/2, N=31, Active, not recruiting, Not yet recruiting --> Active, not recruiting Terminated --> Active, not recruiting
- |||||||||| bortezomib / Generic mfg., arsenic trioxide / Generic mfg., thalidomide / Generic mfg.
Enrollment change, Combination therapy: Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia (clinicaltrials.gov) - Aug 6, 2012 P1, N=5, Completed, Active, not recruiting --> Completed N=24 --> 5
- |||||||||| Acoalan (antithrombin gamma) / Kyowa Hakko Kirin
Trial initiation date: A Clinical Study of KW-3357 in Patients With DIC (clinicaltrials.gov) - Jul 29, 2012 P3, N=10, Completed, Initiation date: Jun 2011 --> Feb 2012 Initiation date: Jun 2011 --> Dec 2011
|